Shots:

• Alexion to receive $60M in cash and 2.1243 ADSs (each ADS represents ½ ordinary share of AstraZeneca) for each Alexion share. The deal values Alexion at $175/ share with a 45% premium to the closing price on Dec 11- 2020
• Alexion will own ~15% of the combined company. The acquisition will bolster AstraZeneca’s footprints in rare disease and enhance its presence in immunology
• The duo will work together to build Alexion's pipeline of 11 molecules across 20+ clinical- programs in rare diseases and beyond. The new company will lead to a WW expansion of Alexion’s portfolio and is expected to deliver double-digit average annual revenue growth through 2025

 ­ Ref: Businesswire | Image: Al Jazeera